Melanogenesis of quality markers in Vernonia anthelmintica Injection based on UPLC-Q-TOF-MS combined network pharmacology.
10.19540/j.cnki.cjcmm.20221201.703
- Author:
Lin LUO
1
;
Yan-Yuan ZHANG
1
;
Cheng WANG
2
;
Si-Lu HUANG
1
;
Xiao-Qin WANG
2
;
Bo ZHANG
3
Author Information
1. Key Laboratory of Xinjiang Phytomedicine Resource and Utilization,Ministry of Education, School of Pharmacy, Shihezi University Shihezi 832002, China.
2. Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University Chengdu 610106, China.
3. Key Laboratory of Xinjiang Phytomedicine Resource and Utilization,Ministry of Education, School of Pharmacy, Shihezi University Shihezi 832002, China Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University Chengdu 610106, China.
- Publication Type:Journal Article
- Keywords:
UPLC-Q-TOF-MS;
Vernonia anthelmintica Injection;
melanogenesis;
network pharmacology;
quality marker
- MeSH:
Animals;
Vernonia/chemistry*;
Melanins/metabolism*;
Zebrafish/metabolism*;
Network Pharmacology;
Molecular Docking Simulation;
Apigenin/pharmacology*;
Drugs, Chinese Herbal/pharmacology*;
Chromatography, High Pressure Liquid
- From:
China Journal of Chinese Materia Medica
2023;48(6):1606-1619
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to evaluate the biological effect and mechanism of Vernonia anthelmintica Injection(VAI) on melanin accumulation. The in vivo depigmentation model was induced by propylthiouracil(PTU) in zebrafish, and the effect of VAI on melanin accumulation was evaluated based on the in vitro B16F10 cell model. The chemical composition of VAI was identified according to the high-performance liquid chromatography quadrupole-time-of-flight tandem mass spectrometry(UPLC-Q-TOF-MS). Network pharmaco-logy was applied to predict potential targets and pathways of VAI. A "VAI component-target-pathway" network was established, and the pharmacodynamic molecules were screened out based on the topological characteristics of the network. The binding of active molecules to key targets was verified by molecular docking. The results showed that VAI promoted tyrosinase activity and melanin production in B16F10 cells in a dose-and time-dependent manner and could restore the melanin in the body of the zebrafish model. Fifty-six compounds were identified from VAI, including flavonoids(15/56), terpenoids(10/56), phenolic acids(9/56), fatty acids(9/56), steroids(6/56), and others(7/56). Network pharmacological analysis screened four potential quality markers, including apigenin, chrysoeriol, syringaresinol, and butein, involving 61 targets and 65 pathways, and molecular docking verified their binding to TYR, NFE2L2, CASP3, MAPK1, MAPK8, and MAPK14. It was found that the mRNA expression of MITF, TYR, TYRP1, and DCT in B16F10 cells was promoted. By UPLC-Q-TOF-MS and network pharmacology, this study determined the material basis of VAI against vitiligo, screened apigenin, chrysoeriol, syringaresinol, and butein as the quality markers of VAI, and verified the efficacy and internal mechanism of melanogenesis, providing a basis for quality control and further clinical research.
